

January 14, 2026

**To,**  
**Dy. General Manager**  
**Department of Corporate Services,**  
**BSE Ltd.,**  
**P. J. Towers, Dalal Street,**  
**Fort, Mumbai – 400 001**

**Ref: Scrip Code: 543322**

Dear Sirs,

**To,**  
**The Manager – Listing,**  
**National Stock Exchange of India Ltd.,**  
**Plot No. C/1, G Block,**  
**Bandra Kurla Complex,**  
**Bandra (E), Mumbai – 400 051**

**Ref: Scrip Name: ALIVUS**

**Sub:- Board Meeting**

We have to inform you that, pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Thursday, January 22, 2026 inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and nine months ended 31st December, 2025.

Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Company has intimated its 'designated persons' regarding the closure of the Trading Window from December 31, 2025 to January 24, 2026 (both days inclusive) for the purpose of approval of Unaudited Financial Results for quarter and nine months ended 31st December, 2025.

The above is for your information.

Thanking you.

Yours faithfully,  
**For Alivus Life Sciences Limited**  
 (formerly Glenmark Life Sciences Limited)

**Rudalf Corriea**  
**Company Secretary & Compliance Officer**

**Alivus Life Sciences Limited** (formerly Glenmark Life Sciences Limited)

**Corporate Office:**

Technopolis Knowledge Park, A wingOffice No. 401 to 407,  
 4th Floor, Mahakali Caves Road, Andheri ( E), Mumbai400093

T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: [complianceofficer@alivus.com](mailto:complianceofficer@alivus.com) | W: [www.alivus.com](http://www.alivus.com)

**Registered Office:**

Plot No 170-172, Chandramouli Industrial Estate  
 Mohol Bazarpath, Solapur 413 213, India

